Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies

Abstract

The success of cancer therapy has been significantly hampered by various mechanisms of therapeutic resistance. Chief among these mechanisms is the presence of clonal heterogeneity within an individual tumor mass. The introduction of the concept of cancer stem cells (CSCs)—a rare and immature subpopulation with tumorigenic potential that contributes to intratumoral heterogeneity—has deepened our understanding of drug resistance. Given the characteristics of CSCs, such as increased drug-efflux activity, enhanced DNA-repair capacity, high metabolic plasticity, adaptability to oxidative stress, and/or upregulated detoxifying aldehyde dehydrogenase (ALDH) enzymes, CSCs have been recognized as a theoretical reservoir for resistant diseases. Implicit in this recognition is the possibility that CSC-targeted therapeutic strategies might offer a breakthrough in overcoming drug resistance in cancer patients. Herein, we summarize the generation of CSCs and our current understanding of the mechanisms underlying CSC-mediated therapeutic resistance. This extended knowledge has progressively been translated into novel anticancer therapeutic strategies and significantly enriched the available options for combination treatments, all of which are anticipated to improve clinical outcomes for patients experiencing CSC-related relapse.

Keywords

cancer stem cells (CSCs) / combination therapy / CSC-targeted therapy / drug resistance

References

[1] BrayF, Laversanne M, SungH, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263.

[2] QinS, JiangJ, LuY, et al. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther. 2020; 5(1):228.

[3] DongreA, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019; 20(2):69-84.

[4] LohJ-J, MaS. Hallmarks of cancer stemness. Cell Stem Cell. 2024; 31(5):617-639.

[5] LewisAC, KatsLM. Non-genetic heterogeneity, altered cell fate and differentiation therapy. EMBO Mol Med. 2021; 13(3):e12670.

[6] AyobAZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018; 25(1):20.

[7] LiuY, WangH. Biomarkers and targeted therapy for cancer stem cells. Trends Pharmacol Sci. 2024; 45(1):56-66.

[8] LiouG-Y. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019; 106:1-7.

[9] YangY, LiX, WangT, Guo Q, XiT, ZhengL. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol. 2020; 13(1):60.

[10] LiuC, QiangJ, DengQ, et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 2021; 81(23):5919-5934.

[11] XuJ, LiL, ShiP, CuiH, YangL. The crucial roles of Bmi-1 in cancer: implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int J Mol Sci. 2022; 23(15):8231.

[12] ZhuY, HuangS, ChenS, et al. SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial–mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer. Cell Death Dis. 2021; 12(5):449.

[13] RegadT. Tissue-specific cancer stem cells: reality or a mirage? Trans Med Rep. 2017;1(1).

[14] RegadT, SayersT, ReesR. Principles of Stem Cell Biology and Cancer: Future Applications and Therapeutics. John Wiley & Sons; 2015.

[15] DasM, LawS. Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. Int J Biochem Cell Biol. 2018; 103:115-124.

[16] Hernández-CamareroP, JiménezG, López-Ruiz E, BarungiS, MarchalJA, Perán M. Revisiting the dynamic cancer stem cell model: importance of tumour edges. Crit Rev Oncol Hematol. 2018; 131:35-45.

[17] GoldsteinM, KastanMB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015; 66:129-143.

[18] KlappV, Álvarez-Abril B, LeuzziG, KroemerG, CicciaA, GalluzziL. The DNA damage response and inflammation in cancer. Cancer Discovery. 2023; 13(7):1521-1545.

[19] GroellyFJ, FawkesM, DaggRA, Blackford AN, TarsounasM. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023; 23(2):78-94.

[20] ShibueT, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629.

[21] PanY, ZhouS, LiY, Parshad B, LiW, HaagR. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells. J Control Release. 2021; 330:1106-1117.

[22] XieXP, LaksDR, SunD, et al. Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. Dev Cell. 2022; 57(1):32-46.e8.

[23] MingH, LiB, JiangJ, et al. Protein degradation: expanding the toolbox to restrain cancer drug resistance. J Hematol Oncol. 2023; 16(1):6.

[24] ErinN, Grahovac J, BrozovicA, EfferthT. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updates. 2020; 53:100715.

[25] Maugeri-SaccàM, Bartucci M, De MariaR. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther. 2012; 11(8):1627-1636.

[26] JiaoX, Velasco-Velázquez MA, WangM, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018; 78(7):1657-1671.

[27] EymeKM, Sammarco A, JhaR, et al. Targeting de novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models. Sci Transl Med. 2023; 15(679):eabq6288.

[28] YoshidaGJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015; 34(1):111.

[29] TuyK, Rickenbacker L, HjelmelandAB. Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. Redox Biol. 2021; 44:101953.

[30] CostaRGA, SilvaSLR, DiasIRSB, et al. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biol. 2023; 62:102692.

[31] MaY, ZhuY, ShangL, et al. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling. Oncogene. 2023; 42(18):1419-1437.

[32] GorodetskaI, Offermann A, PüschelJ, et al. ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR-and RAR-dependent transcription. Theranostics. 2024; 14(2):714-737.

[33] HanJ, WonM, KimJH, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev. 2020; 49(22):7856-7878.

[34] MaiY, SuJ, YangC, Xia C, FuL. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mol Cancer. 2023; 22(1):171.

[35] WongCC, XuJ, BianX, et al. In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance. Gastroenterology. 2020; 159(6):2163-2180.e6.

[36] BaysoyA, BaiZ, SatijaR, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023; 24(10):695-713.

[37] TakaoS, DingQ, MatsubaraS. Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. J Hepatobiliary Pancreat Sci. 2012; 19(6):614-620.

[38] BayikD, LathiaJD. Cancer stem cell–immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021; 21(8):526-536.

[39] ClaraJA, MongeC, YangY, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells—a clinical update. Nat Rev Clin Oncol. 2020; 17(4):204-232.

[40] IshimotoT, NaganoO, YaeT, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011; 19(3):387-400.

[41] HuangT, SongX, XuD, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020; 10(19):8721-8743.

[42] SellS, Nicolini A, FerrariP, M BiavaP. Cancer: a problem of developmental biology; scientific evidence for reprogramming and differentiation therapy. Curr Drug Targets. 2016; 17(10):1103-1110.

[43] YangL, ShiP, ZhaoG, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020; 5(1):8.

[44] GuY, WangY, HeL, et al. Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via hedgehog signaling. Mol Cancer. 2021; 20:132.

[45] ChengL-H, HsuC-C, TsaiH-W, et al. ASPM activates hedgehog and Wnt signaling to promote small cell lung cancer stemness and progression. Cancer Res. 2023; 83(6):830-844.

[46] WangJ, YuH, DongW, et al. N6-methyladenosine–mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways. Gastroenterology. 2023; 164(6):990-1005.

[47] ZhangW, RuanX, LiY, et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway. Theranostics. 2022; 12(4):1500-1517.

[48] HeY, JiangX, DuanL, et al. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol Cancer. 2021; 20:156.

[49] JiangN, ZouC, ZhuY, et al. HIF-1α-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling. Theranostics. 2020; 10(6):2553-2570.

[50] NedeljkovićM, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge. Cells. 2019; 8(9):957.

[51] BlanpainC. Tracing the cellular origin of cancer. Nature Cell Biol. 2013; 15(2):126-134.

[52] BlanpainC, SimonsBD. Unravelling stem cell dynamics by lineage tracing. Nat Rev Mol Cell Biol. 2013; 14(8):489-502.

[53] DzierzakE, BigasA. Blood development: hematopoietic stem cell dependence and independence. Cell Stem Cell. 2018; 22(5):639-651.

[54] HöferT, Rodewald H-R. Differentiation-based model of hematopoietic stem cell functions and lineage pathways. Blood. 2018; 132(11):1106-1113.

[55] Garcia-MayeaY, MirC, MassonF, Paciucci R, LLeonartME. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Sem Cancer Biol. 2020; 60:166-180.

[56] BaiX, NiJ, BeretovJ, Graham P, LiY. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 2018; 69:152-163.

[57] YamanakaS. Pluripotent stem cell-based cell therapy—promise and challenges. Cell Stem Cell. 2020; 27(4):523-531.

[58] HurwitzSN, JungSK, KurreP. Hematopoietic stem and progenitor cell signaling in the niche. Leukemia. 2020; 34(12):3136-3148.

[59] NovakJSS, BakshSC, FuchsE. Dietary interventions as regulators of stem cell behavior in homeostasis and disease. Genes Dev. 2021; 35(3-4):199-211.

[60] ZhuS, ZhaoD, YanL, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun. 2018; 9(1):500.

[61] Rodriguez-RamirezC, Zhang Z, WarnerKA, et al. p53 inhibits Bmi-1-driven self-renewal and defines salivary gland cancer stemness. Clin Cancer Res. 2022; 28(21):4757-4770.

[62] BansalN, Bartucci M, YusuffS, et al. BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer. Clin Cancer Res. 2016; 22(24):6176-6191.

[63] SariIN, PhiLTH, JunN, WijayaYT, LeeS, KwonHY. Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. Cells. 2018; 7(11):208.

[64] LegniniI, Emmenegger L, ZappuloA, et al. Spatiotemporal, optogenetic control of gene expression in organoids. Nature Methods. 2023; 20(10):1544-1552.

[65] SivakumarS, QiS, ChengN, et al. TP53 promotes lineage commitment of human embryonic stem cells through ciliogenesis and sonic hedgehog signaling. Cell Rep. 2022; 38(7):110395.

[66] LiB, MingH, QinS, et al. HSPA8 activates Wnt/β-catenin signaling to facilitate BRAF V600E colorectal cancer progression by CMA-mediated CAV1 degradation. Adv Sci. 2024; 11(3):2306535.

[67] BhattacharyaR, Banerjee Mustafi S, StreetM, DeyA, Dwivedi SKD. Bmi-1: at the crossroads of physiological and pathological biology. Genes Dis. 2015; 2(3):225-239.

[68] CodispotiB, Rinaldo N, ChiarellaE, et al. Recombinant TAT-BMI-1 fusion protein induces ex vivo expansion of human umbilical cord blood-derived hematopoietic stem cells. Oncotarget. 2017; 8(27):43782-43798.

[69] BiehsB, HuJK-H, StrauliNB, et al. BMI1 represses Ink4a/Arf and Hox genes to regulate stem cells in the rodent incisor. Nature Cell Biol. 2013; 15(7):846-852.

[70] HerzogAE, WarnerKA, ZhangZ, et al. The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021; 12(11):988.

[71] LiangY, YangL, XieJ. The role of the hedgehog pathway in chemoresistance of gastrointestinal cancers. Cells. 2021; 10(8):2030.

[72] YanR, PengX, YuanX, et al. Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol. 2013; 36(5):421-435.

[73] XiaoY, Thoresen DT, WilliamsJS, et al. Neural hedgehog signaling maintains stem cell renewal in the sensory touch dome epithelium. Proc Natl Acad Sci. 2015; 112(23):7195-7200.

[74] ZhangC, LiC, HeF, CaiY, YangH. Identification of CD44⁺ CD24⁺ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011; 137(11):1679-1686.

[75] ZhangJ, FanJ, ZengX, et al. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B. 2021; 11(3):609-620.

[76] SalikB, YiH, HassanN, et al. Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer Cell. 2020; 38(2):263-278.

[77] TakebeN, HarrisPJ, WarrenRQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011; 8(2):97-106.

[78] Takahashi-YanagaF, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010; 16(12):3153-3162.

[79] KouryJ, ZhongL, HaoJ. Targeting signaling pathways in cancer stem cells for cancer treatment. Stem Cells Int. 2017; 2017(1):2925869.

[80] PommierSJ, Hernandez A, HanE, et al. Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities. Ann Surg Oncol. 2012; 19(2):527-535.

[81] ShahM, Cardenas R, WangB, et al. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. Mol Cancer. 2017;16:38.

[82] ZhangH-L, WangP, LuM-Z, Zhang S-D, ZhengL. c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol Lett. 2019; 17(5):4487-4493.

[83] SuR, DongL, LiY, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020; 38(1):79-96.e11.

[84] MichelucciA, Di Cristofano C, LamiA, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol. 2009; 18(4):200-205.

[85] SamuelsY, Diaz, Jr., LA, Schmidt-KittlerO, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005; 7(6):561-573.

[86] KawamotoA, YokoeT, TanakaK, et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep. 2012; 27(1):51-57.

[87] MuellerAC, PiperM, GoodspeedA, et al. Induction of ADAM10 by radiation therapy drives fibrosis, resistance, and epithelial-to-mesenchyal transition in pancreatic cancer. Cancer Res. 2021; 81(12):3255-3269.

[88] ZhangN, NgAS, CaiS, LiQ, YangL, Kerr D. Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer. Lancet Oncol. 2021; 22(8):e358-e368.

[89] YangJ, AntinP, BerxG, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6):341-352.

[90] VlashiE, ChenAM, BoyrieS, et al. Radiation-induced dedifferentiation of head and neck cancer cells into cancer stem cells depends on human papillomavirus status. Int J Radiat Oncol Biol Phys. 2016; 94(5):1198-1206.

[91] BastosLGR, de Marcondes PG, de-Freitas-JuniorJCM, et al. Progeny from irradiated colorectal cancer cells acquire an EMT-like phenotype and activate Wnt/β-catenin pathway. J Cell Biochem. 2014; 115(12):2175-2187.

[92] Al-AssarO, Demiciorglu F, LunardiS, et al. Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. Radiother Oncol. 2014; 111(2):243-251.

[93] KimE, YounH, KwonT, et al. PAK1 tyrosine phosphorylation is required to induce epithelial–mesenchymal transition and radioresistance in lung cancer cells. Cancer Res. 2014; 74(19):5520-5531.

[94] ZengQ, LiuY, LiuJ, et al. Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells. Cell Death Dis. 2019; 10(8):588.

[95] ChangL, GrahamPH, HaoJ, et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev. 2014; 33(2):469-496.

[96] DongL, ZhangX, XiangW, Ni J, ZhouW, LiH. Post-transcription mediated Snail stabilization is involved in radiation exposure induced invasion and migration of hepatocarcinoma cells. Biomed Pharmacother. 2018; 103:767-772.

[97] GuH, HuangT, ShenY, et al. Reactive oxygen species-mediated tumor microenvironment transformation: the mechanism of radioresistant gastric cancer. Oxid Med Cell Longevity. 2018; 2018(1):5801209.

[98] NakayamaA, Ninomiya I, HaradaS, et al. Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. Int J Oncol. 2016; 49(5):1890-1898.

[99] LinJ-C, TsaiJ-T, ChaoT-Y, Ma H-I, LiuW-H. The STAT3/Slug axis enhances radiation-induced tumor invasion and cancer stem-like properties in radioresistant glioblastoma. Cancers. 2018; 10(12):512.

[100] KongeJ, Leteurtre F, GoislardM, et al. Breast cancer stem cell-like cells generated during TGFβ-induced EMT are radioresistant. Oncotarget. 2018; 9(34):23519-23531.

[101] Marie-EgyptienneDT, Lohse I, HillRP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013; 341(1):63-72.

[102] QureshiR, AroraH, RizviMA. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett. 2015; 356(2):321-331.

[103] NagarajanD, MeloT, DengZ, Almeida C, ZhaoW. ERK/GSK3β/Snail signaling mediates radiation-induced alveolar epithelial-to-mesenchymal transition. Free Radic Biol Med. 2012; 52(6):983-992.

[104] WangL, ZhaoY, XiongY, et al. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the cathepsin L/CUX1 pathway. Exp Cell Res. 2018; 362(2):424-435.

[105] EspinozaI, MieleL. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett. 2013; 341(1):41-45.

[106] KimR-K, Kaushik N, SuhY, et al. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget. 2016; 7(33):53430-53442.

[107] DongP, KonnoY, WatariH, Hosaka M, NoguchiM, SakuragiN. The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med. 2014; 12:231.

[108] HeY, Mingyan E, WangC, LiuG, ShiM, LiuS. CircVRK1 regulates tumor progression and radioresistance in esophageal squamous cell carcinoma by regulating miR-624-3p/PTEN/PI3K/AKT signaling pathway. Int J Biol Macromol. 2019; 125:116-123.

[109] ZhangJ, TianX-J, XingJ. Signal transduction pathways of EMT induced by TGF-β SHH, and WNT and their crosstalks. J Clin Med. 2016; 5(4):41.

[110] CarlC, FlindtA, HartmannJ, et al. Ionizing radiation induces a motile phenotype in human carcinoma cells in vitro through hyperactivation of the TGF-beta signaling pathway. Cell Mol Life Sci. 2016; 73(2):427-443.

[111] LagadecC, VlashiE, Della DonnaL, DekmezianC, PajonkF. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012; 30(5):833-844.

[112] ZhouS-L, ZhouZ-J, HuZ-Q, et al. CXCR2/CXCL5 axis contributes to epithelial–mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 2015; 358(2):124-135.

[113] WangC, LiS, LiuJ, et al. Silencing of S-phase kinase-associated protein 2 enhances radiosensitivity of esophageal cancer cells through inhibition of PI3K/AKT signaling pathway. Genomics. 2020; 112(5):3504-3510.

[114] ChoiY-J, BaekG-Y, ParkH-R, Jo S-K, JungU. Smad2/3-Regulated expression of DLX2 is associated with Radiation-Induced Epithelial-Mesenchymal transition and radioresistance of A549 and MDA-MB-231 human cancer cell lines. PLoS One. 2016; 11(1):e0147343.

[115] KimJ, KongJ, ChangH, Kim H, KimA. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. Oncotarget. 2016; 7(51):85021-85032.

[116] TangDG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012; 22(3):457-472.

[117] VarelaI, Menendez P, Sanjuan-PlaA. Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors. Oncotarget. 2017; 8(39):66742-66746.

[118] VermeulenL, de Sousa e Melo F, RichelDJ, MedemaJP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012; 13(2):e83-e89.

[119] TurnerC, Kohandel M. Quantitative approaches to cancer stem cells and epithelial–mesenchymal transition. Sem Cancer Biol. 2012; 22:374-378.

[120] WernerB, ScottJG, SottorivaA, Anderson ARA, TraulsenA, AltrockPM. The cancer stem cell fraction in hierarchically organized tumors can be estimated using mathematical modeling and patient-specific treatment trajectories. Cancer Res. 2016; 76(7):1705-1713.

[121] ShangS, YangC, ChenF, et al. ID1 expressing macrophages support cancer cell stemness and limit CD8⁺ T cell infiltration in colorectal cancer. Nat Commun. 2023; 14(1):7661.

[122] ChenX, YangM, YinJ, et al. Tumor-associated macrophages promote epithelial–mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling. Cell Commun Signaling. 2022; 20(1):92.

[123] ZhangR, DongM, TuJ, et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct Target Ther. 2023; 8(1):97.

[124] ZhuangJ, ShenL, LiM, et al. Cancer-associated fibroblast–derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res. 2023; 83(10):1611-1627.

[125] SunL, HuangC, ZhuM, et al. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis. Theranostics. 2020; 10(26):11950-11962.

[126] HeB, GaoR, LvS, et al. Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness. Signal Transduct Target Ther. 2023; 8(1):275.

[127] KathawalaRJ, GuptaP, Ashby, Jr.,CR, ChenZ-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updates. 2015; 18:1-17.

[128] HouY, ZhuQ, LiZ, et al. The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017; 8(3):e2659.

[129] NobiliS, Lapucci A, LandiniI, CoronnelloM, Roviello G, MiniE. Role of ATP-binding cassette transporters in cancer initiation and progression. Sem Cancer Biol. 2020; 60:72-95.

[130] WuZ-X, TengQ-X, CaiC-Y, et al. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochem Pharmacol. 2019; 166:120-127.

[131] WangJ-Q, LiJY, TengQ-X, et al. Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells. Cancers. 2020; 12(2):466.

[132] VaillantF, MerinoD, LeeL, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013; 24(1):120-129.

[133] ShiotaM, Fujimoto N, ImadaK, et al. Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst. 2016;108(7):djw005.

[134] KuwanoM, Shibata T, WatariK, OnoM. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019; 110(5):1536-1543.

[135] BommertKS, Effenberger M, LeichE, et al. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia. 2013; 27(2):441-450.

[136] KangY, HuW, IvanC, et al. Role of focal adhesion kinase in regulating YB–1–mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013; 105(19):1485-1495.

[137] RigalliJP, Tocchetti GN, AranaMR, et al. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016; 376(1):165-172.

[138] LiY, LuhCJ, BurnsKA, et al. Endocrine-disrupting chemicals (EDCs): in vitro mechanism of estrogenic activation and differential effects on ER target genes. Environ Health Perspect. 2013; 121(4):459-466.

[139] RuizML, Rigalli JP, AriasA, et al. Estrogen receptor-α mediates human multidrug resistance associated protein 3 induction by 17α-ethynylestradiol. Biochem Pharmacol. 2013; 86(3):401-409.

[140] AriasA, Rigalli JP, VillanuevaSSM, et al. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity. Toxicology. 2014; 320:46-55.

[141] ChristinJR, WangC, ChungC-Y, et al. Stem cell determinant SOX9 promotes lineage plasticity and progression in basal-like breast cancer. Cell Rep. 2020; 31(10):107742.

[142] DomeniciG, Aurrekoetxea-Rodríguez I, SimõesBM, et al. A Sox2–Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene. 2019; 38(17):3151-3169.

[143] CuiJ, Christin JR, ReiszJA, et al. Targeting ABCA12-controlled ceramide homeostasis inhibits breast cancer stem cell function and chemoresistance. Sci Adv. 2023; 9(48):eadh1891.

[144] BaoL, WuJ, DodsonM, et al. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol Carcinog. 2017; 56(6):1543-1553.

[145] SasakiN, Ishiwata T, HasegawaF, et al. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. Cancer Sci. 2018; 109(4):1135-1146.

[146] PanneerselvamJ, Mohandoss P, PatelR, et al. DCLK1 regulates tumor stemness and cisplatin resistance in non-small cell lung cancer via ABCD-Member-4. Molec Ther Oncolyt. 2020; 18:24-36.

[147] JeterCR, LiuB, LiuX, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011; 30(36):3833-3845.

[148] QuaziF, MoldayRS. Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants. J Biol Chem. 2013; 288(48):34414-34426.

[149] GuoQ, Grimmig T, GonzalezG, et al. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. J Biol Chem. 2018; 293(28):11166-11178.

[150] ZhouS, Schuetz JD, BuntingKD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 2001; 7(9):1028-1034.

[151] SkvortsovS, Debbage P, LukasP, SkvortsovaI. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Sem Cancer Biol. 2015; 31:36-42.

[152] CarruthersRD, AhmedSU, RamachandranS, et al. Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Res. 2018; 78(17):5060-5071.

[153] MinW, BruhnC, GrigaraviciusP, et al. Poly (ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation. Nat Commun. 2013; 4(1):2993.

[154] WangH, YangES, JiangJ, Nowsheen S, XiaF. DNA damage–induced cytotoxicity is dissociated from BRCA1’s DNA repair function but is dependent on its cytosolic accumulation. Cancer Res. 2010; 70(15):6258-6267.

[155] ZhangP, SunY, MaL. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14(4):481-487.

[156] ZhangP, WeiY, WangL, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nature Cell Biol. 2014; 16(9):864-875.

[157] ChafferCL, Marjanovic ND, LeeT, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154(1):61-74.

[158] AntonelliM, Strappazzon F, ArisiI, et al. ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. Oncotarget. 2017; 8(13):21692-21709.

[159] McGrailDJ, LinCC-J, DaiH, et al. Defective replication stress response is inherently linked to the cancer stem cell phenotype. Cell Rep. 2018; 23(7):2095-2106.

[160] EspositoF, Giuffrida R, RacitiG, PuglisiC, ForteS. Wee1 kinase: a potential target to overcome tumor resistance to therapy. Int J Mol Sci. 2021; 22(19):10689.

[161] RedmerT, WalzI, KlingerB, et al. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 2017; 6(1):e291.

[162] LinJ-C, TsaiJ-T, ChaoT-Y, Ma H-I, LiuW-H. The STAT3/Slug axis enhances radiation-induced tumor invasion and cancer stem-like properties in radioresistant glioblastoma. Cancers. 2018; 10(12):512.

[163] KambleD, Mahajan M, DhatR, SitasawadS. Keap1-Nrf2 pathway regulates ALDH and contributes to radioresistance in breast cancer stem cells. Cells. 2021; 10(1):83.

[164] LuY, LiangY, ZhengX, Deng X, HuangW, ZhangG. EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo−/radioresistance in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2019; 38(1):82.

[165] Le GrandM, MukhaA, PüschelJ, et al. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. Theranostics. 2020; 10(14):6411-6429.

[166] ManicG, Signore M, SistiguA, et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2018; 67(5):903-917.

[167] Bernardino-SgherriJ, Siberchicot C, AuvréF, et al. Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein. Oncogene. 2021; 40(19):3460-3469.

[168] DrápelaS, Bouchal J, JollyMK, CuligZ, Souček K. ZEB1: a critical regulator of cell plasticity, DNA damage response, and therapy resistance. Front Mol Biosci. 2020;7:36.

[169] Nolfi-DoneganD, Braganza A, ShivaS. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020; 37:101674.

[170] Bayona-BafaluyMP, Montoya J, Ruiz-PesiniE. Oxidative phosphorylation system and cell culture media. Trends Cell Biol. 2021; 31(8):618-620.

[171] BianX, JiangH, MengY, Li Y, FangJ, LuZ. Regulation of gene expression by glycolytic and gluconeogenic enzymes. Trends Cell Biol. 2022; 32(9):786-799.

[172] BrunnerJS, FinleyLWS. SnapShot: cancer metabolism. Mol Cell. 2021; 81(18):3878-3878.e1.

[173] LeeSY, JeongEK, JuMK, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017; 16:10.

[174] RattiganKM, ZarouMM, HelgasonGV. Metabolism in stem cell–driven leukemia: parallels between hematopoiesis and immunity. Blood. 2023; 141(21):2553-2565.

[175] YangZ, ZhangC, LiuX, CheN, FengY, Xuan Y. SETD5 regulates glycolysis in breast cancer stem-like cells and fuels tumor growth. Am J Pathol. 2022; 192(4):712-721.

[176] SangR, FanR, DengA, et al. Degradation of hexokinase 2 blocks glycolysis and induces gsdme-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy. J Med Chem. 2023; 66(13):8464-8483.

[177] WangB, ZhouY, ZhangP, Li J, LuX. Solasonine inhibits cancer stemness and metastasis by modulating glucose metabolism via Wnt/β-catenin/snail pathway in osteosarcoma. Am J Chin Med. 2023; 51(05):1293-1308.

[178] ZhangY, WangY, ZhaoG, Orsulic S, MateiD. Metabolic dependencies and targets in ovarian cancer. Pharmacol Ther. 2023; 245:108413.

[179] LiuPP, LiaoJ, TangZJ, et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 2014; 21(1):124-135.

[180] GoidtsV, Bageritz J, PuccioL, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene. 2012; 31(27):3235-3243.

[181] HammoudiN, Riaz Ahmed KB, Garcia-PrietoC, HuangP. Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer. 2011; 30(8):508-525.

[182] EmminkBL, Verheem A, van HoudtWJ, et al. The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics. 2013; 91:84-96.

[183] LiW, LiX, WangW, et al. Tumor suppressor gene oxidored-nitro domain-containing protein 1 regulates nasopharyngeal cancer cell autophagy, metabolism, and apoptosis in vitro. Int J Biochem Cell Biol. 2013; 45(9):2016-2026.

[184] LiuG, LuoQ, LiH, LiuQ, JuY, SongG. Increased oxidative phosphorylation is required for stemness maintenance in liver cancer stem cells from hepatocellular carcinoma cell line HCCLM3 cells. Int J Mol Sci. 2020; 21(15):5276.

[185] ThirusanguP, RayU, Sarkar BhattacharyaS, et al. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma. Oncogene. 2022; 41(33):4003-4017.

[186] BiL, RenY, FengM, et al. HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res. 2021; 81(8):2015-2028.

[187] DongC, YuanT, WuY, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013; 23(3):316-331.

[188] RoeschA, VulturA, BogeskiI, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell. 2013; 23(6):811-825.

[189] LagadinouED, SachA, CallahanK, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-341.

[190] JaniszewskaM, Suvà ML, RiggiN, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012; 26(17):1926-1944.

[191] RaggiC, TaddeiML, SaccoE, et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol. 2021; 74(6):1373-1385.

[192] VlashiE, Lagadec C, VergnesL, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci. 2011; 108(38):16062-16067.

[193] VlashiE, Lagadec C, VergnesL, et al. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res Treat. 2014; 146(3):525-534.

[194] LambR, Bonuccelli G, OzsváriB, et al. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: understanding WNT/FGF-driven anabolic signaling. Oncotarget. 2015; 6(31):30453-30471.

[195] CuyàsE, Corominas-Faja B, MenendezJA. The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget. 2014; 5(12):3970-3982.

[196] ZhangY, JiangS, HeF, et al. Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML. Genome Biol. 2023; 24(1):199.

[197] FargeT, SalandE, de ToniF, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discovery. 2017; 7(7):716-735.

[198] LeeK, Giltnane JM, BalkoJM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017; 26(4):633-647.e7.

[199] LambR, Ozsvari B, BonuccelliG, et al. Dissecting tumor metabolic heterogeneity: telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. Oncotarget. 2015; 6(26):21892-21905.

[200] JonesCL, Stevens BM, D’AlessandroA, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018; 34(5):724-740.e4.

[201] AlcaláS, Villarino L, Ruiz-CañasL, et al. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy. J Exp Clin Cancer Res. 2024; 43(1):33.

[202] de BeauchampL, Himonas E, HelgasonGV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022; 36(1):1-12.

[203] Peiris-PagèsM, Martinez-Outschoorn UE, PestellRG, SotgiaF, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. 2016; 18:55.

[204] BaudotA, de la Torre V, ValenciaA. Mutated genes, pathways and processes in tumours. EMBO Rep. 2010; 11(10):805-810.

[205] LaBargeMA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res. 2010; 16(12):3121-3129.

[206] AguilarE, Marin de Mas I, ZoddaE, et al. Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program. Stem Cells. 2016; 34(5):1163-1176.

[207] SosaMS, Bragado P, Aguirre-GhisoJA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014; 14(9):611-622.

[208] LouieE, NikS, ChenJ, et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 2010; 12(6):R94.

[209] BomkenS, Fišer K, HeidenreichO, VormoorJ. Understanding the cancer stem cell. Br J Cancer. 2010; 103(4):439-445.

[210] MedemaJP. Cancer stem cells: the challenges ahead. Nature Cell Biol. 2013; 15(4):338-344.

[211] BayikD, LathiaJD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021; 21(8):526-536.

[212] KrsticJ, Trivanovic D, JaukovicA, SantibanezJF, Bugarski D. Metabolic plasticity of stem cells and macrophages in cancer. Front Immunol. 2017; 8:939.

[213] MehlaK, SinghPK. Metabolic regulation of macrophage polarization in cancer. Trend Cancer. 2019; 5(12):822-834.

[214] Ricci-VitianiL, Pallini R, BiffoniM, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468(7325):824-828.

[215] WangR, Bhattacharya R, YeX, et al. Endothelial cells activate the cancer stem cell-associated NANOGP 8 pathway in colorectal cancer cells in a paracrine fashion. Mol Oncol. 2017; 11(8):1023-1034.

[216] LonardoE, Frias-Aldeguer J, HermannPC, HeeschenC. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle. 2012; 11(7):1282-1290.

[217] HayesJD, Dinkova-Kostova AT, TewKD. Oxidative stress in cancer. Cancer Cell. 2020; 38(2):167-197.

[218] OsukaS, Sampetrean O, ShimizuT, et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells. 2013; 31(4):627-640.

[219] RyooI, LeeS, KwakM-K. Redox modulating NRF2: a potential mediator of cancer stem cell resistance. Oxid Med Cell Longevity. 2016; 2016:2428153.

[220] TonelliC, ChioIIC, TuvesonDA. Transcriptional regulation by Nrf2. Antioxid Redox Signaling. 2018; 29(17):1727-1745.

[221] LuoM, BaoL, XueY, et al. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. J Clin Invest. 2024; 134(6):e171166.

[222] JiangX, Stockwell BR, ConradM. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282.

[223] DongY, TuR, LiuH, QingG. Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat. Signal Transduct Target Ther. 2020; 5(1):124.

[224] DavidCJ, ChenM, AssanahM, Canoll P, ManleyJL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010; 463(7279):364-368.

[225] LiY, ChenH, XieX, et al. PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells. Cancer Res. 2023; 83(3):398-413.

[226] BellHN, Rebernick RJ, GoyertJ, et al. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell. 2022; 40(2):185-200.e6.

[227] ZöllerM. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011; 11(4):254-267.

[228] TamadaM, NaganoO, TateyamaS, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012; 72(6):1438-1448.

[229] KwonT, Kyung Rho J, Cheol LeeJ, et al. An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib. Exp Mol Med. 2015; 47(5):e165.

[230] KimS-U, ParkY-H, KimJ-M, et al. Dominant role of peroxiredoxin/JNK axis in stemness regulation during neurogenesis from embryonic stem cells. Stem Cells. 2014; 32(4):998-1011.

[231] ChandimaliN, JeongDK, KwonT. Peroxiredoxin II regulates cancer stem cells and stemness-associated properties of cancers. Cancers. 2018; 10(9):305.

[232] SrinivasUS, TanBWQ, VellayappanBA, JeyasekharanAD. ROS and the DNA damage response in cancer. Redox Biol. 2019; 25:101084.

[233] HouG-X, LiuP-P, ZhangS, et al. Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. Cell Death Dis. 2018; 9(2):89.

[234] IannicielloA, ZarouMM, RattiganKM, et al. ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Sci Transl Med. 2021; 13(613):eabd5016.

[235] MoW, LiuS, ZhaoX, et al. ROS scavenging nanozyme modulates immunosuppression for sensitized cancer immunotherapy. Adv Healthcare Mater. 2023; 12(21):2300191.

[236] QinS, LiB, MingH, Nice EC, ZouB, HuangC. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. Biochim Biophys Acta Rev Cancer. 2022; 1877(4):188749.

[237] AlisonMR, GuppyNJ, LimSM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol. 2010; 222(4):335-344.

[238] ZanoniM, Bravaccini S, FabbriF, ArientiC. Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance. Front Med. 2022; 9:795762.

[239] HolahNS, AiadHA-E-S, AsaadNY, Elkhouly EA, LasheenAG. Evaluation of the role of ALDH1 as cancer stem cell marker in colorectal carcinoma: an immunohistochemical study. J Clin Diagn Res. 2017;11(1):EC17.

[240] ZhangR, TuJ, LiuS. Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Sem Cancer Biol. 2022; 82:11-25.

[241] Rodríguez-ZavalaJS, CallejaLF, Moreno-Sánchez R, Yoval-SánchezB. Role of aldehyde dehydrogenases in physiopathological processes. Chem Res Toxicol. 2019; 32(3):405-420.

[242] MorebJS, Muhoczy D, OstmarkB, ZucaliJR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol. 2006; 59:127-136.

[243] van der ZeeM, Sacchetti A, CansoyM, et al. IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126⁺ stem-like component and reduces tumor burden. Cancer Res. 2015; 75(17):3608-3622.

[244] VenkataramaniV, YangY, SchubertMC, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022; 185(16):2899-2917.

[245] SchaffLR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023; 329(7):574-587.

[246] WangL, JungJ, BabikirH, et al. A single-cell Atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nature Cancer. 2022; 3(12):1534-1552.

[247] QiuZ, ZhaoL, ShenJZ, et al. Transcription elongation machinery is a druggable dependency and potentiates immunotherapy in glioblastoma stem cells. Cancer Discovery. 2022; 12(2):502-521.

[248] ChengP, WangJ, WaghmareI, et al. FOXD1–ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res. 2016; 76(24):7219-7230.

[249] WuW, WuY, MayerK, et al. Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma. Transl Oncol. 2020; 13(3):100748.

[250] DinavahiSS, GowdaR, BazewiczCG, et al. Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents. Eur J Med Chem. 2020; 187:111962.

[251] PhanTG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020; 20(7):398-411.

[252] YangJ, TengY. Harnessing cancer stem cell-derived exosomes to improve cancer therapy. J Exp Clin Cancer Res. 2023; 42(1):131.

[253] WuB, ZhangF, YuM, et al. Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell Proliferation. 2012; 45(3):189-198.

[254] XuX-H, PanW, KangL-H, Feng H, SongY-Q. Association of annexin A2 with cancer development. Oncol Rep. 2015; 33(5):2121-2128.

[255] SharmaMC. Annexin A2 (ANX A2): an emerging biomarker and potential therapeutic target for aggressive cancers. Int J Cancer. 2019; 144(9):2074-2081.

[256] ChenC-Y, LinY-S, ChenC-H, Chen Y-J. Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. J Biomed Sci. 2018; 25(1):30.

[257] StaquiciniDI, RangelR, Guzman-RojasL, et al. Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting. Sci Rep. 2017;7(1):4243.

[258] ScholzenT, GerdesJ. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-322.

[259] GeyerFC, Rodrigues DN, WeigeltB, Reis-FilhoJS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012; 19(1):39-53.

[260] ThomasSM, SahuB, RapireddyS, et al. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. ACS Chem Biol. 2013; 8(2):345-352.

[261] ChengCJ, BahalR, BabarIA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015; 518(7537):107-110.

[262] LiX-Q, PeiD-S, QianG-W, et al. The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells. Tumor Biol. 2011; 32(5):863-872.

[263] NovakD, Hüser L, EltonJJ, UmanskyV, Altevogt P, UtikalJ. SOX2 in development and cancer biology. Sem Cancer Biol. 2020; 67:74-82.

[264] TanS, Guschin D, DavalosA, et al. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci. 2003; 100(21):11997-12002.

[265] YokotaE, Yamatsuji T, TakaokaM, et al. Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma. Oncotarget. 2017; 8(61):103063-103076.

[266] WangR-F, WangHY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017; 27(1):11-37.

[267] SadelainM. CAR therapy: the CD19 paradigm. J Clin Invest. 2015; 125(9):3392-3400.

[268] MaudeSL, FreyN, ShawPA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.

[269] SternerRC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69.

[270] KlebanoffCA, Rosenberg SA, RestifoNP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Med. 2016; 22(1):26-36.

[271] RobbinsPF, MorganRA, FeldmanSA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-924.

[272] RapoportAP, Stadtmauer EA, Binder-SchollGK, et al. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Med. 2015; 21(8):914-921.

[273] TanKX, Danquah MK, SidhuA, OngkudonCM, LauSY. Towards targeted cancer therapy: Aptamer or oncolytic virus? Eur J Pharm Sci. 2017;96:8-19.

[274] ZhangY, WangX. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020; 13(1):165.

[275] LiuX, SuK, SunX, et al. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway. J Exp Clin Cancer Res. 2021; 40:132.

[276] ManniW, MinW. Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm. 2022; 3(4):e176.

[277] Da CostaKM, Freire-de-Lima L, Da FonsecaLM, PreviatoJO, Mendonça-Previato L, ValenteRC. ABCB1 and ABCC1 function during TGF-β-induced epithelial-mesenchymal transition: relationship between multidrug resistance and tumor progression. Int J Mol Sci. 2023; 24(7):6046.

[278] AlzahraniAS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Sem Cancer Biol. 2019; 59:125-132.

[279] HerN-H, JeongS-I, ChoK, et al. PPARδ promotes oncogenic redirection of TGF-β1 signaling through the activation of the ABCA1-Cav1 pathway. Cell Cycle. 2013; 12(10):1521-1535.

[280] DerynckR, TurleySJ, AkhurstRJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021; 18(1):9-34.

[281] ZhangL, WangY, XiaT, et al. Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer. Drug Delivery. 2016; 23(8):2970-2979.

[282] ChenC-L, Tsukamoto H, LiuJ-C, et al. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 2013; 123(7):2832-2849.

[283] AdachiK, KoppW, WuG, et al. ESRRB unlocks silenced enhancers for reprogramming to naive pluripotency. Cell Stem Cell. 2018; 23(2):266-275.e6.

[284] LiQ-S, ZhengP-S. ESRRB inhibits the TGFβ signaling pathway to drive cell proliferation in cervical cancer. Cancer Res. 2023; 83(18):3095-3114.

[285] WuC-P, HungC-Y, LusvarghiS, et al. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochem Pharmacol. 2020; 180:114137.

[286] ZhangD, DengY, KukanjaP, et al. Spatial epigenome–transcriptome co-profiling of mammalian tissues. Nature. 2023; 616(7955):113-122.

[287] GongF, ChiuL-Y, MillerKM. Acetylation reader proteins: linking acetylation signaling to genome maintenance and cancer. PLoS Genet. 2016; 12(9):e1006272.

[288] PramanikD, Campbell NR, KarikariC, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011; 10(8):1470-1480.

[289] FergusonLP, DiazE, ReyaT. The role of the microenvironment and immune system in regulating stem cell fate in cancer. Trend Cancer. 2021; 7(7):624-634.

[290] YuanS, Stewart KS, YangY, et al. Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature. 2022; 612(7940):555-563.

[291] ZhangY, YangJ, BronzeMS, Houchen CW, LiM. Interplay of tumor microenvironment factors and cancer stem cell enrichment in pancreatic ductal adenocarcinoma. Gastroenterology. 2021; 161(6):1800-1802.

[292] WigerupC, Påhlman S, BexellD. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016; 164:152-169.

[293] RankinEB, NamJM, GiacciaAJ. Hypoxia: signaling the metastatic cascade. Trend Cancer. 2016; 2(6):295-304.

[294] LeeSY, JeonHM, JuMK, et al. Dlx-2 is implicated in TGF-β-and Wnt-induced epithelial-mesenchymal, glycolytic switch, and mitochondrial repression by Snail activation. Int J Oncol. 2015; 46(4):1768-1780.

[295] OhshioY, Hanaoka J, KontaniK, TeramotoK. Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types. Scand J Immunol. 2014; 80(6):408-416.

[296] Mediavilla-VarelaM, Boateng K, NoyesD, AntoniaSJ. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016; 16(1):176.

[297] HuC, LiuX, RanW, et al. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials. 2017; 144:60-72.

[298] KeshK, GuptaVK, DurdenB, et al. Therapy resistance, cancer stem cells and ECM in cancer: the matrix reloaded. Cancers. 2020; 12(10):3067.

[299] YanY, ZuoX, WeiD. Concise review: emerging role of CD44 in cancer stem cells: A promising biomarker and therapeutic target. Stem Cells Transl Med. 2015; 4(9):1033-1043.

[300] ThapaR, WilsonGD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016; 2016(1):2087204.

[301] ChoiKY, ChungH, MinKH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010; 31(1):106-114.

[302] YangC, HeY, ZhangH, et al. Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo. Oncotarget. 2015; 6(17):15283-15296.

[303] WangH, Agarwal P, ZhaoS, et al. Hyaluronic acid-decorated dual responsive nanoparticles of pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials. 2015; 72:74-89.

[304] ShenY, LiW. HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment. Drug Des Devel Ther. 2018; 12:2285.

[305] BacharG, CohenK, HodR, et al. Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials. 2011; 32(21):4840-4848.

[306] KesharwaniP, Banerjee S, PadhyeS, SarkarFH, IyerAK. Hyaluronic acid engineered nanomicelles loaded with 3, 4-difluorobenzylidene curcumin for targeted killing of CD44⁺ stem-like pancreatic cancer cells. Biomacromolecules. 2015; 16(9):3042-3053.

[307] SohelM, IslamMN, HossainMA, et al. Pharmacological properties to pharmacological insight of sesamin in breast cancer treatment: a literature-based review study. Int J Breast Cancer. 2022; 2022:1-13.

[308] MajdalawiehAF, MassriM, NasrallahGK. A comprehensive review on the anti-cancer properties and mechanisms of action of sesamin, a lignan in sesame seeds (Sesamum indicum). Eur J Pharmacol. 2017; 815:512-521.

[309] LiuX, ZhangY, LiY, et al. Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma. Acta Pharm Sin B. 2021; 11(2):488-504.

[310] TongW, QiuL, QiM, et al. GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism. J Cell Biochem. 2018; 119(4):3641-3652.

[311] TylawskyDE, Kiguchi H, VaynshteynJ, et al. P-selectin-targeted nanocarriers induce active crossing of the blood–brain barrier via caveolin-1-dependent transcytosis. Nat Mater. 2023; 22(3):391-399.

[312] YanR, ZhuH, HuangP, et al. Liquidambaric acid inhibits Wnt/β-catenin signaling and colon cancer via targeting TNF receptor-associated factor 2. Cell Rep. 2022; 38(5):110319.

[313] MuR, SunH, ZengY, et al. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy. J Controlled Release. 2024; 369:458-474.

[314] SabolHM, Ferrari AJ, AdhikariM, et al. Targeting notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021; 81(19):5102-5114.

[315] HanQ, XieQR, LiF, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. Theranostics. 2021; 11(13):6526-6541.

[316] TewariAB, SainiA, SharmaD. Extirpating the cancer stem cell hydra: differentiation therapy and hyperthermia therapy for targeting the cancer stem cell hierarchy. Clin Exp Med. 2023; 23:3125-3145.

[317] MassardC, Deutsch E, SoriaJ-C. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol. 2006; 17(11):1620-1624.

[318] SoriaJ-C, KimES, FayetteJ, Lantuejoul S, DeutschE, HongWK. Chemoprevention of lung cancer. Lancet Oncol. 2003; 4(11):659-669.

[319] ArimaY, Nobusue H, SayaH. Targeting of cancer stem cells by differentiation therapy. Cancer Sci. 2020; 111(8):2689-2695.

[320] ZhouH-M, ZhangJ-G, ZhangX, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021; 6(1):62.

[321] TallmanMS, Andersen JW, SchifferCA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999. Blood. 2002;100(13):4298-4302.

[322] Dela CruzF, Matushansky I. Solid tumor differentiation therapy—is it possible? Oncotarget. 2012; 3(5):559-567.

[323] Lo-CocoF, Avvisati G, VignettiM, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369:111-121.

[324] Dos SantosGA, KatsL, PandolfiPP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013; 210(13):2793-2802.

[325] MartensJHA, Brinkman AB, SimmerF, et al. PML-RARα/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010; 17(2):173-185.

[326] Vitaliano-PrunierA, Halftermeyer J, AblainJ, et al. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood. 2014; 124(25):3772-3780.

[327] AblainJ, LeivaM, PeresL, Fonsart J, AnthonyE, de ThéH. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med. 2013; 210(4):647-653.

[328] BernardiR, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007; 8(12):1006-1016.

[329] AblainJ, RiceK, SoilihiH, de Reynies A, MinucciS, de ThéH. Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature Med. 2014; 20(2):167-174.

[330] RobozGJ, DiNardo CD, SteinEM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020; 135(7):463-471.

[331] PollyeaDA, Tallman MS, de BottonS, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019; 33(11):2575-2584.

[332] LosmanJ-A, KaelinWG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013; 27(8):836-852.

[333] MolenaarRJ, Maciejewski JP, WilminkJW, van NoordenCJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018; 37(15):1949-1960.

[334] MukherjeeJ, Johannessen T-C, OhbaS, et al. Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. Cancer Res. 2018; 78(11):2966-2977.

[335] ZhangX, WangX, WangXQD, et al. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood. 2020; 135(11):845-856.

[336] LosmanJ-A, LooperRE, KoivunenP, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013; 339(6127):1621-1625.

[337] KatsLM, Vervoort SJ, ColeR, et al. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia. 2017; 31(6):1466-1470.

[338] QuekL, DavidMD, KennedyA, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Med. 2018; 24(8):1167-1177.

[339] ChenY, CaoJ, ZhangN, et al. Advances in differentiation therapy for osteosarcoma. Drug Discovery Today. 2020; 25(3):497-504.

[340] HeB-C, ChenL, ZuoG-W, et al. Synergistic antitumor effect of the activated PPARγ and retinoid receptors on human osteosarcoma. Clin Cancer Res. 2010; 16(8):2235-2245.

[341] ZhuangH, ZhangX, ZhuC, et al. Molecular mechanisms of PPAR-γ governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther. 2016; 11(3):255-264.

[342] LuoX, ChenJ, SongW-X, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 2008; 88(12):1264-1277.

[343] SongM, TianX, LuM, et al. Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway. Int J Oncol. 2015; 46(3):1131-1140.

[344] LuY, SunY, ZhuJ, et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway. Cell Death Dis. 2018; 9(1):15.

[345] KhalidAB, KrumSA. Estrogen receptors alpha and beta in bone. Bone. 2016; 87:130-135.

[346] KrumSA. Direct transcriptional targets of sex steroid hormones in bone. J Cell Biochem. 2011; 112(2):401-408.

[347] Lillo OsunaMA, Garcia-Lopez J, El AyachiI, et al. Activation of estrogen receptor alpha by decitabine inhibits osteosarcoma growth and metastasis. Cancer Res. 2019; 79(6):1054-1068.

[348] LeeC-H, HuangY-L, LiaoJ-F, Chiou W-F. Ugonin k-stimulated osteogenesis involves estrogen receptor-dependent activation of non-classical Src signaling pathway and classical pathway. Eur J Pharmacol. 2012;676(1-3):26-33.

[349] PangX-G, CongY, BaoN-R, Li Y-G, ZhaoJ-N. Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway. BioMed Res Int. 2018; 2018(1):1-11.

[350] TiroshI, IzarB, PrakadanSM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016; 352(6282):189-196.

[351] TrapnellC, Cacchiarelli D, GrimsbyJ, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nature Biotechnol. 2014; 32(4):381-386.

[352] JanuchowskiR, Wojtowicz K, ZabelM. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013; 67(7):669-680.

[353] DavidKA, MonganNP, SmithC, Gudas LJ, NanusD. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther. 2010; 9(9):678-684.

[354] RoyR, WillanP, ClarkeR, Farnie G. Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy. Breast Cancer Res. 2010;12(1):O5.

[355] PetitC, LacasB, PignonJ-P, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021; 22(5):727-736.

[356] PetitC, LeeA, MaJ, et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023; 24(6):611-623.

[357] AgudaBD. Modeling microRNA-transcription factor networks in cancer. MicroRNA Cancer Regulation. 2013; 774:149-167.

[358] HatziapostolouM, Polytarchou C, AggelidouE, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011; 147(6):1233-1247.

[359] LandaI, Ibrahimpasic T, BoucaiL, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-1066.

[360] DettmerM, Schmitt A, SteinertH, MochH, Komminoth P, PerrenA. Poorly differentiated oncocytic thyroid carcinoma–diagnostic implications and outcome. Histopathology. 2012; 60(7):1045-1051.

[361] GraweF, CahyaA, FabritiusMP, et al. Course of disease and clinical management of patients with poorly differentiated thyroid carcinoma. Cancers. 2021; 13(21):5309.

[362] YangH, ChenZ, WuM, LeiT, YuH, GeM. Remarkable response in 2 cases of advanced poorly differentiated thyroid carcinoma with liposomal doxorubicin plus cisplatin. Cancer Biol Ther. 2016; 17(6):693-697.

[363] BroseMS, Nutting CM, JarzabB, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 2014; 384(9940):319-328.

[364] SchlumbergerM, TaharaM, WirthLJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372(7):621-630.

[365] ViolaD, Valerio L, MolinaroE, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185-R205.

[366] AntonelliM, RasoA, MascelliS, et al. SMARCB1/INI1 involvement in pediatric chordoma. Am J Surg Pathol. 2017; 41(1):56-61.

[367] BishopJA, Antonescu CR, WestraWH. SMARCB1 (INI-1) deficient carcinomas of the sinonasal tract. Am J Surg Pathol. 2014; 38(9):1282-1289.

[368] HasselblattM, ThomasC, HovestadtV, et al. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol. 2016; 132(1):149-151.

[369] RenardC, Pissaloux D, DecouvelaereAV, BourdeautF, Ranchère D. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors? Cancer Genetics. 2014; 207(9):384-389.

[370] StacchiottiS, CasaliPG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. 2011; 13(4):323-330.

[371] ChenY-L, Liebsch N, KobayashiW, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine. 2013;38(15):E930-E936.

[372] StacchiottiS, LonghiA, FerraresiV, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012; 30(9):914-920.

[373] StacchiottiS, Tamborini E, Lo VulloS, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013; 24(7):1931-1936.

[374] Al-RahawanMM, Siebert JD, MitchellCS, SmithSD. Durable complete response to chemotherapy in an infant with a clival chordoma. Pediatr Blood Cancer. 2012; 59(2):323-325.

[375] LiuT-C, Hamilton N, HawkinsW, GaoF, CaoD. Comparison of WHO classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2013; 37(6):853-859.

[376] TangLH, UntchBR, ReidyDL, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016; 22(4):1011-1017.

[377] LynchTJ, Bondarenko I, LuftA, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-2054.

[378] HookKE, GarzaSJ, LiraME, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012; 11(3):710-719.

[379] SosML, Dietlein F, PeiferM, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci. 2012; 109(42):17034-17039.

[380] MollaogluG, Guthrie MR, BöhmS, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017; 31(2):270-285.

[381] JahchanNS, LimJS, BolaB, et al. Identification and targeting of long-term tumor-propagating cells in small cell lung cancer. Cell Rep. 2016; 16(3):644-656.

[382] TsangSV, Rainusso N, LiuM, et al. LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination. Oncogene. 2022; 41(50):5373-5384.

[383] TornínJ, Mateu-Sanz M, ReyV, et al. Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma. Redox Biol. 2023; 62:102685.

[384] FatmaH, Siddique HR. Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer. Expert Rev Anticancer Ther. 2021; 21(8):853-864.

[385] MohiuddinIS, WeiS-J, KangMH. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(4):165432.

[386] LeiZ-N, TianQ, TengQ-X, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023; 4(3):e265.

[387] ZhangL, ChenW, LiuS, ChenC. Targeting breast cancer stem cells. Int J Biol Sci. 2023; 19(2):552-570.

[388] ZhangZ, QinS, ChenY, et al. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. 2022; 14:e14903.

[389] WangH, GongP, ChenT, et al. Colorectal cancer stem cell states uncovered by simultaneous single-cell analysis of transcriptome and telomeres. Adv Sci. 2021; 8(8):2004320.

[390] ZhengH, PomyenY, HernandezMO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018; 68(1):127-140.

[391] BurguinA, DiorioC, DurocherF. Breast cancer treatments: updates and new challenges. J Pers Med. 2021; 11(8):808.

[392] LathiaJD, MackSC, Mulkearns-HubertEE, ValentimCLL, RichJN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29(12):1203-1217.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).